Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients
- PMID: 34310531
- PMCID: PMC8549120
- DOI: 10.1097/TP.0000000000003907
Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients
Conflict of interest statement
D.L.S. received honoraria for consulting and speaking from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, and Thermo Fisher Scientific. R.K.A has received study/grant support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. S.A. received grant support from the Cystic Fibrosis Foundation, received consulting honoraria from Merck and Gilead, and was an unpaid consultant for BioMX. The other authors declare no conflicts of interest.
Comment in
-
Preemptive Antibody Therapy for Vaccine Breakthrough SARS-CoV-2 Infection in Immunocompromised Patients.Transplantation. 2021 Dec 1;105(12):e282. doi: 10.1097/TP.0000000000003942. Transplantation. 2021. PMID: 34456266 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous